Clinical Trial

Exploration of Dalpiciclib Plus HDACi in HR+/HER2- Advanced Breast Cancer After Failure of CDK4/6 Inhibitor

Name: Exploration of Dalpiciclib Plus HDACi in HR+/HER2- Advanced Breast Cancer After Failure of CDK4/6 Inhibitor — clinical trial record (NCT06556862)
Creator: DataLookout
License: https://creativecommons.org/licenses/by/4.0/

Not Yet Recruiting Phase 2

View on ClinicalTrials.gov →

Summary

A phase II study to explore the efficacy and safety of dalpiciclib plus HDACi in HR+/HER2- advanced breast cancer after the failure of CDK4/6 inhibitor therapy.

Protocol Amendment History 1 amendment

This ClinicalTrials.gov record has been amended once since 2024-08-13.

Trial Details

NCT Number	NCT06556862
Lead Sponsor	Beijing 302 Hospital
Conditions	HR+/HER2- Advanced Breast Cancer
Enrollment	155 participants
Start Date	2025-10-01
Primary Completion	2026-12-31 (estimated)
Study Completion	2028-12-31 (estimated)
Updated on ClinicalTrials.gov	2025-08-13